Dermapharm Holding SE (FRA:DMP) Construction In Progress: €0 Mil (As of Mar. 2026)


FRA:DMP Dermapharm Holding SE FRA:DMP
87 GF Score
Price €46.25
GF Value €39.11
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Construction In Progress?

Dermapharm Holding SE FRA:DMP 87 Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Dermapharm Holding SE Construction In Progress Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Construction In Progress Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:DMP
87GF Score
Dermapharm Holding SE FRA:DMP
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0 Mil mean?
Dermapharm Holding SE (FRA:DMP) has a Construction In Progress of €0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Construction In Progress too high?
Dermapharm Holding SE's current Construction In Progress is €0 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Construction In Progress compare to ZTS and UTHR?
Dermapharm Holding SE's Construction In Progress of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Construction In Progress is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current Construction In Progress is €0 Mil. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current Construction In Progress is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11. GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.

Key valuation signals for FRA:DMP:

  • Construction In Progress: €0 Mil
  • GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
  • GF Score™: 87/100 with 9 warning signs

No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score

Get the complete analysis for FRA:DMP

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.25
Price
€39.11
GF Value